Ebrantil and Diabetes - a phase IV clinical study of FDA data

Summary:

Diabetes is reported as a side effect among people who take Ebrantil (urapidil), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Nexium, and have Myelodysplastic syndrome.

The phase IV clinical study analyzes which people have Diabetes when taking Ebrantil. It is created by eHealthMe based on reports of 1,650 people who have side effects when taking Ebrantil from the FDA, and is updated regularly.

What is Ebrantil?

Ebrantil has active ingredients of urapidil. eHealthMe is studying from 1,656 Ebrantil users. Check the latest studies of Ebrantil.

What is Diabetes?

Diabetes is found to be associated with 2,009 drugs and 2,855 conditions by eHealthMe. Check the latest studies of Diabetes.

On Jul, 16, 2026

1,650 people reported to have side effects when taking Ebrantil.
Among them, 23 people (1.39%) have Diabetes.

Among these 23 people:

How long have people been on Ebrantil when they have Diabetes? *

What is the gender of people who have Diabetes when taking Ebrantil? *

female: 54.55 %
male: 45.45 %

What is the age of people who have Diabetes when taking Ebrantil? *

What are other drugs people take besides Ebrantil? *

What are other side effects people have besides Diabetes? *

Anaemia (lack of blood): 5 people, 21.74%
Thrombocytopenia (decrease of platelets in blood): 5 people, 21.74%
Dehydration (dryness resulting from the removal of water): 4 people, 17.39%
Renal Disorder (kidney disease): 4 people, 17.39%
Circulatory Collapse: 3 people, 13.04%
Iron Deficiency: 3 people, 13.04%
Urinary Tract Infection: 3 people, 13.04%
Blood Creatinine Increased: 3 people, 13.04%
Nephrogenic Anaemia (anaemia due to kidney disease): 3 people, 13.04%
Pain In Extremity: 3 people, 13.04%

What are the existing conditions these people have? *

Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 5 people, 21.74%
Multiple Myeloma (cancer of the plasma cells): 4 people, 17.39%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 3 people, 13.04%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 3 people, 13.04%
Spinal Osteoarthritis (joint cartilage loss in spine): 3 people, 13.04%
Sleep Disorder: 3 people, 13.04%
Pollakiuria (abnormally frequent passage of relatively small quantities or urine): 3 people, 13.04%
Osteoporosis (bones weak and more likely to break): 3 people, 13.04%
Neurogenic Bladder (the normal function of the bladder is to store and empty urine in a coordinated, controlled fashion): 3 people, 13.04%
Cardiac Failure Chronic: 3 people, 13.04%

* Approximation only. Some reports may have incomplete information.

Do you take Ebrantil and have Diabetes?

- Check whether Diabetes is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ebrantil:

Ebrantil (1,656 reports)

Diabetes treatments and more:

Diabetes (466,613 reports)

Browse all side effects of Ebrantil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Diabetes:

Diabetes (2,009 drugs)

Browse all the conditions that are associated with Diabetes:

Diabetes (2,855 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on urapidil (the active ingredients of Ebrantil) and Ebrantil (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.